The initiation of Phase 1 dosing represents a material de-risking step for OPKO's oncology pipeline. Traders should monitor upcoming safety and early efficacy data readouts, which could serve as catalysts for re-rating, especially in a high-unmet-need setting like relapsed/refractory B-cell lymphoma.
Price Chart
Executive Summary
OPKO Health announced the initiation of patient dosing in a Phase 1 trial for MDX2003, a novel tetraspecific T-cell engager targeting relapsed or refractory B-cell lymphoma. Preclinical data supporting the trial were presented at major medical conferences, marking a key milestone in the development of this first-in-class therapy.
Key Facts
- OPKO Health subsidiary ModeX Therapeutics has dosed patients in the Phase 1 trial (NCT07249905) of MDX2003, a first-in-class tetraspecific T-cell engager.
- MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells to enhance tumor killing and prevent immune escape in B-cell lymphoma.
- Preclinical data demonstrating potent anti-tumor activity were presented at ASH 2025 and ESMO TAT 2026.
- The study is evaluating safety, tolerability, pharmacokinetics, and immune activity in adult patients with B-cell lymphoma, with dose-escalation and expansion phases.
Financial Impact
No immediate direct financial impact; early-stage clinical advancement may increase optionality and long-term value potential.
Risk Factors
- Clinical trial may encounter safety or tolerability issues, particularly with T-cell engagers known for cytokine release syndrome.
- Early-phase success does not guarantee later-stage efficacy or regulatory approval.
- Dilution risk if future funding rounds or partnerships are required to advance development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278886 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 8-K | $1.65 $1.49 | ▼ −9.70% | ▼ −13.08% | $1.56 (−5.45%) |
Jul 23, 2026 10w ago | Press Release | $1.17 $1.46 | ▲ +24.79% | ▲ +21.48% | $1.56 (+33.33%) |
Jun 15, 2026 15w ago | Press Release | $1.40 $1.23 | ▼ −12.14% | ▼ −11.39% | $1.56 (+11.43%) |
May 15, 2026 20w ago | DEFA14A | $1.13 $1.39 | ▲ +23.01% | ▲ +21.43% | $1.56 (+38.05%) |
Apr 30, 2026 22w ago | Press Release | $1.13 $1.43 | ▲ +26.55% | ▲ +21.58% | $1.56 (+38.05%) |
Apr 22, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
Apr 21, 2026 23w ago | Press Release | $1.23 $1.15 | ▼ −6.50% | ▼ −9.67% | $1.56 (+26.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access